Short description
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics.
Description
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). Chemomab is advancing in parallel three Phase 2 clinical trials with CM-101 in fibrotic indications and expecting to report data during 2021-2022.
Last funding
Noway Youcantaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Tel Aviv, Tel Aviv, Israel, Asia
Founded on
January 1, 2011
Exited on
March 16, 2021
Went public on
March 16, 2021
Stock symbol
CMMB
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Nopepepe, Noaccess, Noway Youcantaccess, Noaccess, No Way, Noaccess, Cannot Access, Cannot Access, Uh Ohhhh
Sign in for full access
Founders
Adi Mor